Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
NCT04400331Phase 3Completed
- Lead sponsor
- Neurocrine Biosciences (Industry)
- Enrollment
- 154 (actual)
- Start date
- 18 Sep 2020
- Primary completion
- 5 Nov 2025 (actual)
- Study completion
- 5 Nov 2025
- Last update posted
- 17 Jun 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Valbenazine Drug
Conditions and primary outcome
- Chorea, Huntington
Primary outcome
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (Up to 262 weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT04400331.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04400331 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.